Among the millions who have turned to GLP-1 medications like Ozempic as a cornerstone of modern diabetes care, roughly one in ten carry a quiet genetic difference that renders these drugs less effective — not through any failure of the medicine itself, but through a deeper biological resistance written into their DNA. Researchers at Stanford Medicine have traced this resistance to variants in genes governing a hormone-activating enzyme called PAM, offering the first molecular explanation for why some patients plateau where others thrive. The discovery opens a door toward precision medicine in
Rádio Pampa
· Jun 08, 2026
· health
· 3 min de leitura
High
Apuração: Verificado
Genetic variants explain why Ozempic fails for 10% of patients
◉
Health & Medicine
2722 artigos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% correspondência
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% correspondência
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% correspondência
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% correspondência
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% correspondência
Cobertura Relacionada
G1 · Aug 19
Macaé mobiliza 45 salas para atualizar vacinação de menores de 15 anos
Macaé lança campanha de atualização vacinal para menores de 15 anos em 45 pontos de saúde até 1º de setembro, com Dia D …
Agência FAPESP · Aug 19 Pesquisadores desenvolvem vacina inteligente contra chikungunya com vírus que se replica apenas uma vezCientistas da USP criaram uma vacina inovadora contra chikungunya usando vírus geneticamente modificado que se replica a…
G1 · Aug 19 Pastor belga do Senado é afastado após atacar veterinária que segue em estado graveVeterinária terceirizada sofre ataque grave de pastor belga malinois no Senado Federal em Brasília, com mordida no pesco…
Rádio Pampa · Aug 19 Heterossexuais são maioria entre pacientes que descobrem HIV em estágio avançadoEstudo em hospital de Porto Alegre revela que 84% dos pacientes diagnosticados com HIV em estágio avançado são heterosse…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Stanford research identifies genetic variants in 10% of people causing GLP-1 resistance, with limited geopolitical implications but potential for precision medicine disparities between nations.
Escalation Risk
low
Confidence
MED
United States
European Union
Brazil
Global pharmaceutical markets
Advances in precision medicine genetics strengthen U.S. biotech leadership and Stanford's research influence. Unequal access to genetic testing and personalized treatments could widen healthcare disparities between developed and developing nations, affecting pharmaceutical market dynamics and healthcare policy globally.
Similar to the Human Genome Project era (2000s), where genetic discoveries concentrated research power in wealthy nations, potentially creating healthcare inequities between countries with advanced genomic infrastructure and those without.
Lente Econômica
📈
Stanford researchers identify genetic variants in 10% of people causing GLP-1 resistance, explaining poor Ozempic efficacy in some diabetes patients and enabling precision medicine approaches.
Market Signal
mixed
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Diagnostic Testing
Health Insurance
Patients with GLP-1 resistance variants may benefit from earlier identification enabling alternative treatments, reducing ineffective medication use and healthcare costs. However, genetic testing costs may increase upfront expenses for some consumers.
Potential regulatory push for genetic screening before GLP-1 prescription; insurance coverage decisions for pharmacogenomic testing; FDA guidance on precision medicine approaches for diabetes treatment; healthcare systems may adopt genetic profiling protocols.